

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC. and INTELGENX CORP.,
Petitioner,

v.

MONOSOL RX, LLC,
Patent Owner.

Case IPR2017-01557
Patent 8,603,514

PATENT OWNER PRELIMINARY RESPONSE

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. OVERVIEW	4
III. THE PETITION IS TIME-BARRED UNDER 35 U.S.C. § 315(b)	6
IV. CLAIM CONSTRUCTION	7
A. Even The Broadest Reasonable Claim Interpretation Requires That Multiple Unit Doses Be Taken From A Single Cast Film Matrix	7
1. The Express Claim Language Requires Individual Unit Doses That Are Taken From A Single Cast Film Matrix	8
2. This Multi-Dose Film Interpretation Is The Only One That Is Consistent With The Intrinsic Evidence	10
B. Terms Previously Construed By Board	13
V. THE CHALLENGED CLAIMS OF THE '514 PATENT ARE NOT OBVIOUS OVER THE COMBINATION OF ILANGO AND CHEN	14
A. State Of The Art At The Date Of Invention	14
1. Pharmaceutical Films Were A Relatively New Dosage Form	14
2. Little Was Known About The Causes Of Loss Of Drug Content Uniformity In Multi-Dose Films, Much Less Solutions For That Problem	16
B. Deficiencies In Ilango And Chen	17
1. Ilango does not teach making a multi-dose film	17
2. Chen	20
VI. THE BOARD SHOULD EXERCISE ITS DISCRETION UNDER 35 U.S.C. §§ 314(a) AND 325(d) TO DENY THE PETITION	20
VII. CONCLUSION	3030

EXHIBIT LIST

Exhibit No.	Description
2001	Reckitt Benckiser v. DRL Trial Opinion
2002	Par Complaint
2003	Par Proof of Service
2004	Intelgenx Proof of Service

Patent Owner MonoSol Rx, LLC (“PO”) respectfully submits this Patent Owner Preliminary Response to the Petition seeking *inter partes* review of U.S. Patent No. 8,603,514 (“the ’514 Patent”) filed by Par Pharmaceutical, Inc. and Intelgenx Corp. (collectively “Petitioner”) alleging that Claims 1–3, 9, 15, 62–65, 69–73, and 75 of the ’514 Patent (“the Challenged Claims”) are unpatentable. The Petition is one of five IPR petitions filed against the ’514 patent, and one of eleven overall challenges to the patent over the past four years. Patent Owner’s Preliminary Response is timely under 35 U.S.C. § 313 and 37 C.F.R. § 42.107 because it is filed within three months of the Notice of Filing Date. Paper 5 at 2. PO submits that the Petition (1) is time-barred under 35 U.S.C. § 315(b) and 37 C.F.R. § 42.101(b), (2) fails to establish that any of the Challenged Claims is unpatentable, and (3) should be denied using the Board’s discretion under 35 U.S.C. §§ 314(a) and 325(d).

I. INTRODUCTION

The ’514 Patent is directed to pharmaceutical films and is listed in FDA’s Orange Book for Suboxone[®] Film, a treatment for opioid dependence and the first sublingual film ever approved by FDA. Prior to the ’514 Patent, it was widely acknowledged that it was difficult to manufacture pharmaceutical films in a manner that kept an active drug ingredient substantially uniformly distributed throughout the film matrix during casting and drying, *i.e.*, drug content uniformity

or “DCU.” The inventors of the ’514 Patent discovered an elegant solution to the DCU problem—controlling, among other things, the viscosity of the wet matrix of a cast film and various drying parameters, *e.g.*, air flow, in order to prevent active particles from migrating from one unit dose to the next and agglomerating before the film was sufficiently dried to lock them in a substantially uniform distribution. While the Claims do not use the phrase, drug content uniformity is shorthand for the heart of the invention: maintaining drug content uniformity throughout the manufacturing process such that “the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active.” Ex. 1001, ’514 Patent at 67:53–56 (Claim 1), 74:6–9 (Claim 62).

The ’514 Patent has been the subject of multiple validity attacks in both district court and at the PTAB—even withstanding attacks by this same Petitioner. For this reason alone, the Board should exercise its discretion under 35 U.S.C. §§ 314(a) and 325(d) to deny the petition. Indeed, this Petitioner previously challenged the validity of the ’514 Patent in district court, where the court’s opinion, which issued more than 15 months ago, found that Petitioner failed to demonstrate the claims 62, 64, 65, 69, and 73 of the ’514 Patent were unpatentable. Ex. 1023, C.A. 1:13-cv-01674, D.I. 446 at 42. In another previous district court litigation, the court rejected generic manufacturer Dr. Reddy’s Laboratories

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.